Medical Notes

28/08/2026

A hypertensive pregnant woman at 35 weeks' comes with history of pain in abdomen, bleeding per vaginum and loss of fetal movements. On examination the uterus is contracted with increased uterine tone. Fetal heart sounds are absent. The most likely diagnosis is:

a. Placenta previa
b. Hydramnios
c. Premature labor
d. Abruptio placenta

27/08/2026

26/08/2026

Question of tha day

26/08/2026

Choose one

28/06/2026

28/06/2026

27/06/2026

18/05/2026

Treatment of

02/03/2026

As GLP-1 use expands beyond diabetes and obesity, clinicians are seeing a wider range of real-world symptoms,👉 including reports of chronic cough.

Observational data suggest a higher incidence of persistent cough with GLP-1 receptor agonists,👉 even without GERD, raising questions about causality and evaluation.

☑️ For PCPs, the challenge is balancing symptom assessment with the substantial cardiometabolic benefits of continued therapy.

01/03/2026

Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) that is FDA approved for use to slow progression of diabetic kidney disease (DKD).

The American Diabetes Association and Kidney Disease: Improving Global Outcomes 👉jointly recommend👉 finerenone in patients with type 2 diabetes mellitus and chronic kidney disease who have normal serum potassium levels and persistent albuminuria despite maximal renin-angiotensin system inhibition.

Recommendations for finerenone are based on the FIDELIO-DKD trial, which showed that MRA use in this setting can reduce progression of DKD. It is not known whether finerenone is superior to steroidal MRAs (spironolactone or eplerenone) in reducing DKD progression, but finerenone causes less hyperkalemia.